Information Provided By:
Fly News Breaks for April 12, 2017
TXMD
Apr 12, 2017 | 09:38 EDT
Stifel analyst Annabel Samimy believes a short delay in the FDA action date, or PDUFA, is the most likely outcome for TherapeuticsMD after the company received a letter from the agency citing identification of deficiencies. The company does not believe the deficiencies are related to clinical, safety, or manufacturing issues, Samimy tells investors in a research note after speaking to management. The analyst thinks the issues could be resolved by end of summer and keeps a Buy rating on TherapeuticsMD with a $20 price target
News For TXMD From the Last 2 Days
There are no results for your query TXMD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.